# Caris Life Sciences Inc. (CAI) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $32.85, market value $9.3 billion.

## Valuation
- **P/E (trailing): 19.4×**. Caris Life Sciences Inc. trades at 19.4× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 88.3×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 1.27**. A PEG of 1.27 is in the range usually read as fairly priced for its growth.
- **Price / sales: 9.4×**. Each dollar of revenue is priced at 9.4×.
- **Price / book: 15.7×**. The shares trade at 15.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 51.0×**. Enterprise value is 51.0× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.3%** (5-yr avg 1.5%). Free cash flow equals 1.3% of the market value, in line with its five-year average of 1.5%.
- **Earnings yield: 5.1%**. The inverse of the P/E: 5.1% of the price is earned each year.

## Profitability
- **Operating margin: 15.5%**. 15.5% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -8.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -11.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 75.7%**. Return on all capital, debt included, is 75.7%: comfortably above what that capital costs.
- **Return on assets: 9.3%**. Each dollar of assets produces 9.3% of profit.

## Growth
- **Revenue growth (1 yr): 97.0%**. Revenue grew 97.0% over the last year.
- **EPS growth (1 yr): 69.8%**. Earnings per share rose 69.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.66**. Debt is 0.66 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Caris Life Sciences Inc. holds more cash than debt.
- **Current ratio: 7.85** (quick 7.85). Current assets cover the next year's liabilities 7.85 times.
- **Altman Z-score: 12.66**. A Z-score of 12.66 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Caris Life Sciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover Caris Life Sciences Inc.; the consensus is buy, with an average price target of $32.46 (-1% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.7%** (YTD 19.0%, 3-mo 96.7%). The shares are up 6.7% over twelve months including dividends.
- **From 52-week high: -10.0%** (131.5% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.40** (volatility 68%). Beta of 1.40 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CAI · Page: https://foliofundamentals.com/stocks/cai

Not investment advice.